Stockscreener 앱 받기
2.36
3.28%
-0.08
시장 영업 전:
2.41
0.05
+2.12%
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Director Sells 4,000,000 Shares of Stock - MarketBeat
Foundation Fighting Blindness Retinal Degeneration Fund Sells 4,000,000 Shares of Opus Genetics Inc (IRD) - GuruFocus
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) By Investing.com - Investing.com Australia
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) - Investing.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference | Associated Press | syndication news - Enidnews.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewswire
Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27% - simplywall.st
B. Riley Securities Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
B. Riley Initiates Opus Genetics at Buy With $9 Price Target - marketscreener.com
B.Riley initiates Opus Genetics stock with Buy rating on gene therapy potential - Investing.com Canada
Opus Genetics Says Independent Panel Backs Phase 1/2 Trial in Best Disease After Safety Review - marketscreener.com
Opus Genetics rises on update from eye disease study (IRD) - Seeking Alpha
Opus Genetics (IRD) Advances in Clinical Trial for Best Disease Treatment - GuruFocus
Opus Genetics advances Best disease gene therapy trial after positive safety review - Investing.com Canada
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease - marketscreener.com
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Is Opus Genetics Inc. stock positioned well for digital economy2025 Earnings Impact & Daily Market Momentum Tracking - Newser
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades after rate cutsMarket Risk Analysis & Smart Allocation Stock Reports - Newser
Why Opus Genetics Inc. (R3X1) stock gets analyst attentionOptions Play & High Accuracy Trade Signal Alerts - Newser
Equities Analysts Offer Predictions for Opus Genetics FY2025 Earnings - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades under stagflationAnalyst Downgrade & Fast Entry High Yield Stock Tips - Newser
Why institutional investors increase stakes in Opus Genetics Inc. (R3X1) stockMarket Growth Summary & Verified Entry Point Signals - Newser
Will Opus Genetics Inc. (R3X1) stock outperform small cap peers2025 Market WrapUp & Growth Focused Stock Reports - Newser
Brokers Issue Forecasts for Opus Genetics FY2025 Earnings - Defense World
Opus Genetics (NASDAQ:IRD) Upgraded to "Strong-Buy" at Brookline Capital Management - MarketBeat
Why Opus Genetics Inc. stock remains on buy listsJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - Newser
Brookline Capital Management Upgrades Opus Genetics (NASDAQ:IRD) to Strong-Buy - Defense World
Opus Genetics, Inc. (IRD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Why Opus Genetics Inc. (R3X1) stock remains stable2025 Technical Patterns & Long-Term Growth Portfolio Plans - Newser
Will Opus Genetics Inc. (R3X1) stock test record highs in 2025Weekly Profit Summary & Long-Term Capital Growth Strategies - Newser
Brookline Capital Markets initiates Buy rating on Opus Genetics stock By Investing.com - Investing.com Canada
Opus Genetics, Inc.'s (NASDAQ:IRD) large institutional owners must be happy as stock continues to impress, up 12% over the past week - simplywall.st
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT - Insider Monkey
Opus Genetics (NASDAQ:IRD) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
12 Hot Penny Stocks to Invest in Right Now - Insider Monkey
Opus Genetics (NASDAQ:IRD) Coverage Initiated at Piper Sandler - MarketBeat
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Piper Sandler Initiates Coverage on IRD with Overweight Rating a - GuruFocus
Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage - TradingView
Piper Sandler initiates coverage on Opus Genetics stock with Overweight rating - Investing.com Canada
Opus Genetics, Inc. $IRD is BIOS Capital Management LP’s 2nd Largest Position - Defense World
Opus Genetics Inc R3X1 Stock Analysis and ForecastCurrency Fluctuation Impact & Consistent High Yield Stocks - earlytimes.in
Opus Genetics, Inc. $IRD is BIOS Capital Management LP's 2nd Largest Position - MarketBeat
Opus Genetics’ New Study on Vision Improvement: What Investors Need to Know - MSN
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Bristol-Myers Squibb (BMY) and PACS Group Inc (PACS) - The Globe and Mail
How Opus Genetics Inc. (R3X1) stock reacts to fiscal policies2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
Is Opus Genetics Inc. (R3X1) stock a safe buy pre earningsJuly 2025 Patterns & Verified Technical Signals - newser.com
What is the fair value estimate for Opus Genetics Inc. (R3X1) stock in 2025Take Profit & Risk Controlled Daily Trade Plans - newser.com
Opus Genetics (IRD) Price Target Increased by 13.45% to 7.87 - MSN
1.08%
0.91%
자본화:
|
볼륨(24시간):